Patents Assigned to Cylene Pharmaceuticals
  • Pyrazolopyrimidines and related heterocycles as kinase inhibitors
    Patent number: 8367681
    Abstract: The invention provides compounds of general formula (I) that inhibit selected kinases (Pim and/or CK2 kinases) and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain infections and immunological disorders.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: February 5, 2013
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Mustapha Haddach, Joe Tran
  • PROTEIN KINASE MODULATORS
    Publication number: 20120208792
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: December 8, 2011
    Publication date: August 16, 2012
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Peter C. Chua, Mustapha Haddach, Johnny Y. Nagasawa, Fabrice Pierre, Jeffrey P. Whitten
  • OXINDOLE COMPOUNDS
    Publication number: 20120190669
    Abstract: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.
    Type: Application
    Filed: January 20, 2012
    Publication date: July 26, 2012
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Mustapha Haddach, Johnny Yasuo Nagasawa
  • DEUTERATED SERINE-THREONINE PROTEIN KINASE MODULATORS
    Publication number: 20120129849
    Abstract: The present invention provides deuterated compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The deuterated compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such deuterated compounds as therapeutic agents.
    Type: Application
    Filed: September 23, 2011
    Publication date: May 24, 2012
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Mustapha HADDACH, David M. Ryckman
  • SUBSTITUTED QUINOBENZOXAZINE ANALOGS
    Publication number: 20120122804
    Abstract: The present invention relates to quinobenzoxazines analogs having the general formula: and pharmaceutically acceptable salts, esters and prodrugs thereof; wherein A, U, V, W, X and Z are substituents. The present invention also relates to methods for using such compounds.
    Type: Application
    Filed: March 30, 2007
    Publication date: May 17, 2012
    Applicant: Cylene Pharmaceuticals, Inc.
    Inventors: Jeffrey P. Whitten, Michael Schwaebe, Adam Siddiqui-Jain, Terrance Moran
  • Protein kinase modulators
    Patent number: 8168651
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: May 1, 2012
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Mustapha Haddach, Johnny Y. Nagasawa, Fabrice Pierre, Jeffrey P. Whitten
  • Oxindole compounds
    Patent number: 8124649
    Abstract: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.
    Type: Grant
    Filed: June 30, 2009
    Date of Patent: February 28, 2012
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Mustapha Haddach, Johnny Yasuo Nagasawa
  • FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
    Publication number: 20110263581
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: February 25, 2011
    Publication date: October 27, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Peter C. CHUA, Fabrice Pierre, Jeffrey P. Whitten
  • QUINOLONE ANALOGS AND METHODS RELATED THERETO
    Publication number: 20110218184
    Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Application
    Filed: March 9, 2011
    Publication date: September 8, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Johnny Yasuo NAGASAWA, Fabrice Pierre, Mustapha Haddach, Michael Schwaebe, Levan Darjania, Jeffrey P. Whitten
  • POLYMORPHS AND SALTS OF A KINASE INHIBITOR
    Publication number: 20110160240
    Abstract: The present invention relates to novel crystalline polymorphic salt forms of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid, processes for the preparation thereof, compositions thereof and their use in methods of treatment and prevention of conditions mediated by casein kinase (CK) and/or poly(ADP-ribose)polymerase (PARD).
    Type: Application
    Filed: November 23, 2010
    Publication date: June 30, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: David M. Ryckman, Michael Schwaebe
  • PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS
    Publication number: 20110152240
    Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.
    Type: Application
    Filed: November 15, 2010
    Publication date: June 23, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Mustapha Haddach, Joe A. Tran, Fabrice Pierre, Collin F. Regan, Nicholas B. Raffaele, Suchitra Ravula, David M. Ryckman
  • Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
    Patent number: 7956064
    Abstract: The invention relates in part to fused tricyclic compounds having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. The fused tricyclic compounds of the invention can modulate casein kinase (CK) activity and/or poly(ADP-ribose)polymerase (PARP) activity. The invention also relates in part to methods for using such fused tricyclic compounds.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: June 7, 2011
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Jeffrey P. Whitten
  • PYRIDINONE ANALOGS
    Publication number: 20110112086
    Abstract: The present invention provides pyridinone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing pyridinone analogs, and methods of using the same.
    Type: Application
    Filed: June 8, 2007
    Publication date: May 12, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Fabrice Pierre, Michael Schwaebe
  • Quinolone analogs and methods related thereto
    Patent number: 7928100
    Abstract: The present invention provides novel quinolone compounds and pharmaceutical composition thereof which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing such compounds and compositions, and methods of making and using the same.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: April 19, 2011
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Johnny Yasuo Nagasawa, Fabrice Pierre, Mustapha Haddach, Michael Schwaebe, Levan Darjania, Jeffrey P. Whitten
  • PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS
    Publication number: 20110071115
    Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, infections, and certain immunological disorders.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 24, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: MUSTAPHA HADDACH, DAVID M. RYCKMAN, NICHOLAS RAFFAELE
  • NOVEL TRICYCLIC PROTEIN KINASE MODULATORS
    Publication number: 20110071136
    Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 24, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC
    Inventors: Mustapha HADDACH, Fabrice PIERRE
  • Therapeutic kinase modulators
    Patent number: 7910600
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: March 22, 2011
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Fabrice Pierre, Mustapha Haddach
  • NOVEL PROTEIN KINASE MODULATORS
    Publication number: 20110065698
    Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and modulating polymerase activity. Molecules of the invention can modulate protein kinase CK2 activity, Pim kinase activity and/or FMS-like tyrosine kinase (Flt) activity. The invention also relates in part to methods for using such molecules.
    Type: Application
    Filed: August 26, 2010
    Publication date: March 17, 2011
    Applicant: CYLENE PHARMACEUTICALS, INC.
    Inventors: Fabrice PIERRE, Mustapha HADDACH, Collin F. REGAN, David M. RYCKMAN
  • TRICYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF
    Publication number: 20110065712
    Abstract: The invention provides compounds that inhibit CK2 and/or Pim kinases and compositions containing such compounds. These tricyclic compounds and compositions containing them are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, pathogenic infections, and certain immunological disorders.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 17, 2011
    Applicant: CYLENE PHARMACEUTICALS , INC.
    Inventors: Mustapha HADDACH, Fabrice Pierre
  • Methods of preparing quinolone analogs
    Patent number: 7834180
    Abstract: Compounds having formula 1: are produced by contacting a compound having formula (6A) with a compound having formula (7), or tautomers thereof, in the presence of a non-nucleophilic base, wherein V, A, Z, L, L1, W, X, B?, R and n are as defined herein.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: November 16, 2010
    Assignee: Cylene Pharmaceuticals, Inc.
    Inventors: Peter C. Chua, Johnny Y. Nagasawa, Michael Schwaebe, Fabrice Pierre